BiotechTube

Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Excessive Sleepiness

Conditions

Excessive Sleepiness, Shift-work Disorder

Trial Timeline

Aug 1, 2024 → Dec 1, 2026

NCT ID
NCT06568367

About Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo

Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo is a phase 3 stage product being developed by Axsome Therapeutics for Excessive Sleepiness. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06568367. Target conditions include Excessive Sleepiness, Shift-work Disorder.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT06568367Phase 3Recruiting
NCT06413433Phase 3Recruiting
NCT05972044Phase 3Completed

Competing Products

8 competing products in Excessive Sleepiness

See all competitors
ProductCompanyStageHype Score
Placebo + PF-03654746PfizerPhase 2
51
JZP-110Jazz PharmaceuticalsPhase 2
49
Solriamfetol + PlaceboAxsome TherapeuticsApproved
82
Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
74
Solriamfetol Oral Tablet + PlaceboAxsome TherapeuticsApproved
82
Fibrin Sealant Grifols + EVICELGrifolsPhase 3
74
ORX142 TabletsCentessa PharmaceuticalsPhase 1
28
VSF-173Vanda PharmaceuticalsPhase 2
44

Other Products from Axsome Therapeutics

Solriamfetol + PlaceboApproved
82
Solriamfetol 75 MGApproved
82
AXS-05 + BupropionApproved
82
Solriamfetol Oral Tablet + PlaceboApproved
82
AXS-05 (dextromethorphan and bupropion) oral tabletsPhase 3
74